ACTUATE THERAPEUTICS

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 مايو 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 مايو 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 أبريل 2025 09:24:10 بحسب Nasdaq GlobeNewswire

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

17 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

25 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

06 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

07 يناير 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 ديسمبر 2024 07:28:17 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to be Added to Russell 2000® Index

26 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 نوفمبر 2024 07:00:03 بحسب Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 أكتوبر 2024 17:39:24 بحسب Nasdaq GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

11 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 سبتمبر 2024 08:10:56 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

20 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire